U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. University Fertility Laboratory, Inc. - 577584 - 08/03/2023
  1. Warning Letters

CLOSEOUT LETTER

University Fertility Laboratory, Inc. MARCS-CMS 577584 —

Delivery Method:
Via Email
Product:
Biologics

Recipient:
Recipient Name
Dr. Omid A. Khorram
Recipient Title
Medical Director
University Fertility Laboratory, Inc.

23550 Hawthorne Blvd., Suite 210
Torrance, CA 90505
United States

okhorram@yahoo.com
Issuing Office:
Division of Biological Products Operations II

United States


Dear Dr. Khorram:

The Food and Drug Administration has completed evaluation of your corrective actions in response to our Warning Letter # OBPO 19-006 issued May 30, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Amy Graf
Compliance Officer

Back to Top